<code id='438CA390BB'></code><style id='438CA390BB'></style>
    • <acronym id='438CA390BB'></acronym>
      <center id='438CA390BB'><center id='438CA390BB'><tfoot id='438CA390BB'></tfoot></center><abbr id='438CA390BB'><dir id='438CA390BB'><tfoot id='438CA390BB'></tfoot><noframes id='438CA390BB'>

    • <optgroup id='438CA390BB'><strike id='438CA390BB'><sup id='438CA390BB'></sup></strike><code id='438CA390BB'></code></optgroup>
        1. <b id='438CA390BB'><label id='438CA390BB'><select id='438CA390BB'><dt id='438CA390BB'><span id='438CA390BB'></span></dt></select></label></b><u id='438CA390BB'></u>
          <i id='438CA390BB'><strike id='438CA390BB'><tt id='438CA390BB'><pre id='438CA390BB'></pre></tt></strike></i>

          Home / Wikipedia / knowledge

          knowledge


          knowledge

          author:hotspot    Page View:42

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In